Managing acquired resistance in EGFR-mutated non–small cell lung cancer

Research output: Contribution to journalArticlepeer-review

Abstract

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) deliver high response rates with relatively modest toxicity in patients with advanced EGFR-mutated non–small cell lung cancer. Despite this, nearly all tumors eventually develop resistance to first-line therapy. At present, the only standard treatment option for patients with acquired resistance is cytotoxic chemotherapy. In this article, we review the latest research into methods of targeting acquired resistance to EGFR TKI therapy, including third-generation EGFR TKIs that target the T790M resistance mutation and other novel agents in development.

Original languageEnglish (US)
Pages (from-to)528-532
Number of pages5
JournalClinical Advances in Hematology and Oncology
Volume13
Issue number8
StatePublished - Aug 1 2015

Keywords

  • EGFR mutations
  • Epidermal growth factor receptors
  • Non–small cell lung cancer
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Managing acquired resistance in EGFR-mutated non–small cell lung cancer'. Together they form a unique fingerprint.

Cite this